SCHEMBL30922661

SCHEMBL30922661

CN(C)CC1(COc2nc(OC(F)(F)F)c3cnc(Cl)c(F)c3n2)CC1

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 20/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24536822 0.89 KRAS (0.36) KRAS
SCHEMBL29679962 0.89 KRAS (0.36) KRAS
SCHEMBL27191216 0.75 KRAS (0.42) KRAS
SCHEMBL24535940 0.74 KRAS (0.42) KRAS
SCHEMBL24535869 0.74 KRAS (0.42) KRAS
SCHEMBL29680503 0.74 KRAS (0.42) KRAS
SCHEMBL30229727 0.74 KRAS (0.38) KRAS
SCHEMBL30707490 0.73 KRAS (0.47) KRAS
SCHEMBL24536776 0.72 KRAS (0.34) KRAS
SCHEMBL29680468 0.72 KRAS (0.34) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598921-A1 MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE Amgen Inc. (US) 2025-08-13 — — EP disclosed
WO-2024107686-A1 MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2024-05-23 — — WO disclosed
Send feedback